Apo A-I Modulating Therapies
- First Online:
- Cite this article as:
- Nicholls, S.J. Curr Cardiol Rep (2011) 13: 537. doi:10.1007/s11886-011-0223-0
- 76 Downloads
The substantial residual risk of cardiovascular events despite the implementation of effective lowering of low-density lipoprotein cholesterol highlights the need to develop additional cardioprotective therapies. Evidence from population and animal studies suggests that high-density lipoproteins (HDLs), the protective lipid particles, may represent a target for therapeutic modification. As a result intensive efforts are in progress to develop new agents that promote HDL activity. Among these different approaches, a range of strategies that target apolipoprotein A-I, the major protein carried on HDL, are being evaluated.